Patents Assigned to Point Therapeutics
  • DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES
    Publication number: 20240140964
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: July 28, 2023
    Publication date: May 2, 2024
    Applicant: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
  • Combination therapy involving diaryl macrocyclic compounds
    Patent number: 11666574
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: June 6, 2023
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Wei Deng, Dayong Zhai, Laura Rodon, Brion W. Murray, Jingrong J. Cui, Nathan V. Lee
  • Combination therapy involving diaryl macrocyclic compounds
    Patent number: 11654145
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: May 23, 2023
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Wei Deng, Dayong Zhai, Laura Rodon, Brion W. Murray, Jingrong J. Cui
  • Macrocycles for use in treating disease
    Patent number: 11634433
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: April 25, 2023
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
  • Chiral diaryl macrocycles and uses thereof
    Patent number: 11452725
    Abstract: This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: September 27, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong J. Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Wei Deng, Zhongdong Huang
  • Combination therapy involving diaryl macrocyclic compounds
    Patent number: 11291667
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: April 5, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong Jean Cui, Dayong Zhai
  • Macrocyclic compounds for treating disease
    Patent number: 11286265
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: March 29, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Macrocyclic compounds and uses thereof
    Patent number: 11286264
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 29, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Macrocyclic compounds and uses thereof
    Patent number: 11155563
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: October 26, 2021
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Macrocycles for use in treating disease
    Patent number: 11142533
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: October 12, 2021
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
  • Chiral diaryl macrocycles as modulators of protein kinases
    Patent number: 11008337
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, of the formula I: pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: May 18, 2021
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong J. Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Wei Deng, Jane Ung
  • Macrocyclic compounds for treating disease
    Patent number: 10745416
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: August 18, 2020
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Macrocycle kinase inhibitors
    Patent number: 10689400
    Abstract: The present disclosure relates to certain macrocyclic kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same to treat disease.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: June 23, 2020
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Jane Ung
  • MACROCYCLIC COMPOUNDS FOR TREATING DISEASE
    Publication number: 20200190110
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Application
    Filed: January 30, 2020
    Publication date: June 18, 2020
    Applicant: Turning Point Therapeutics, Inc.
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Diaryl macrocycles as modulators of protein kinases
    Patent number: 10618912
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: April 14, 2020
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
  • ANTI-TUMOR AGENTS
    Publication number: 20080221068
    Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
    Type: Application
    Filed: October 15, 2007
    Publication date: September 11, 2008
    Applicant: Point Therapeutics, Inc.
    Inventors: Barbara P. Wallner, Glenn T. Miller
  • Anti-tumor agents
    Patent number: 7282484
    Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: October 16, 2007
    Assignee: Point Therapeutics, Inc.
    Inventors: Barbara P. Wallner, Glenn T. Miller
  • Stimulation of hematopoietic cells in vitro
    Patent number: 7276371
    Abstract: Methods, compositions, and devices for stimulating the number and/or differentiation of hematopoietic cells in vitro are provided. The methods involve contacting the hematopoietic cells with an inhibitor of dipeptidyl peptidase (DPIV) in the absence of exogenously provided cytokines.
    Type: Grant
    Filed: December 1, 2003
    Date of Patent: October 2, 2007
    Assignee: Point Therapeutics, Inc.
    Inventors: William Bachovchin, Barbara P. Wallner
  • Regulation of substrate activity
    Patent number: 7265118
    Abstract: A method for regulating substrate activity in vivo is useful for the treatment of medical disorders such as inflammation, arteriolosclerosis and angiogenesis. The method involves the administration of an effective amount of a DPP-IV inhibitor to a patient in need of such treatment.
    Type: Grant
    Filed: July 27, 2005
    Date of Patent: September 4, 2007
    Assignee: Point Therapeutics, Inc.
    Inventor: Barbara P. Wallner
  • Anti-tumor agents
    Patent number: 7259138
    Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: August 21, 2007
    Assignee: Point Therapeutics, Inc.
    Inventors: Barbara P. Wallner, Glenn T. Miller